AZRX vs. COCP, LPCN, UBX, MBRX, GOVX, EDSA, FLGC, MEIP, GELS, and EQ
Should you be buying AzurRx BioPharma stock or one of its competitors? The main competitors of AzurRx BioPharma include Cocrystal Pharma (COCP), Lipocine (LPCN), Unity Biotechnology (UBX), Moleculin Biotech (MBRX), GeoVax Labs (GOVX), Edesa Biotech (EDSA), Flora Growth (FLGC), MEI Pharma (MEIP), Gelteq (GELS), and Equillium (EQ). These companies are all part of the "medical" sector.
AzurRx BioPharma vs.
AzurRx BioPharma (NASDAQ:AZRX) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, community ranking, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.
Cocrystal Pharma's return on equity of -94.62% beat AzurRx BioPharma's return on equity.
Cocrystal Pharma has a consensus target price of $7.00, suggesting a potential upside of 379.45%. Given Cocrystal Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Cocrystal Pharma is more favorable than AzurRx BioPharma.
6.3% of AzurRx BioPharma shares are held by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are held by institutional investors. 7.3% of AzurRx BioPharma shares are held by company insiders. Comparatively, 28.1% of Cocrystal Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, Cocrystal Pharma had 4 more articles in the media than AzurRx BioPharma. MarketBeat recorded 4 mentions for Cocrystal Pharma and 0 mentions for AzurRx BioPharma. Cocrystal Pharma's average media sentiment score of 0.93 beat AzurRx BioPharma's score of 0.00 indicating that Cocrystal Pharma is being referred to more favorably in the news media.
Cocrystal Pharma is trading at a lower price-to-earnings ratio than AzurRx BioPharma, indicating that it is currently the more affordable of the two stocks.
AzurRx BioPharma has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Comparatively, Cocrystal Pharma has a beta of 2.13, suggesting that its share price is 113% more volatile than the S&P 500.
AzurRx BioPharma received 201 more outperform votes than Cocrystal Pharma when rated by MarketBeat users. However, 77.42% of users gave Cocrystal Pharma an outperform vote while only 74.26% of users gave AzurRx BioPharma an outperform vote.
Summary
Cocrystal Pharma beats AzurRx BioPharma on 13 of the 15 factors compared between the two stocks.
Get AzurRx BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AZRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AzurRx BioPharma Competitors List
Related Companies and Tools
This page (NASDAQ:AZRX) was last updated on 5/23/2025 by MarketBeat.com Staff
Buy AZRX Stock Free AZRX Stock Alerts